Diamonds in the rough: Harnessing tumor-Associated myeloid cells for cancer therapy

Frontiers in Immunology

Volumn 9, Issue OCT, 2018, Pages

  Clappaert, Emile J ^a,b   Murgaski, Aleksandar ^a,b   Damme, Helena Van ^a,b   Kiss, Mate ^a,b   Laoui, Damya ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cancer immunotherapy; Myeloid derived suppressor cells; Tumor microenvironment; Tumor Associated dendritic cells; Tumor Associated macrophages; Tumor Associated neutrophils

Indexed keywords

BONE MARROW CELL; DENDRITIC CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; NEUTROPHIL; PATHOLOGY; PROCEDURES; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MACROPHAGES; MYELOID CELLS; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; NEUTROPHILS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85055207942     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.02250     Document Type: Review

References (249)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell (2011) 144:646-74. doi: 10.1016/j.cell.2011.02.013.
2. Mendes F, Domingues C, Rodrigues-Santos P, Abrantes AM, Gonçalves AC, Estrela J, et al. The role of immune system exhaustion on cancer cell escape and anti-Tumor immune induction after irradiation. Biochim Biophys Acta Rev Cancer (2016) 1865:168-75. doi: 10.1016/j.bbcan.2016.02.002.
3. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. (2012) 30:459-89. doi:10.1146/annurev-immunol-020711-074942.
4. De Vlaeminck Y, González-Rascón A, Goyvaerts C, Breckpot K. Cancer-Associated myeloid regulatory cells. Front Immunol. (2016) 7:113. doi:10.3389/fimmu.2016.00113.
5. Steinberg SM, Shabaneh TB, Zhang P, Martyanov V, Li Z, Malik BT, et al. Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors. Cancer Res. (2017) 77:1599-610. doi:10.1158/0008-5472.CAN-16-1755.
6. Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. (2017) 5:3-8. doi:10.1158/2326-6066.CIR-16-0297.
7. Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol. (2018) 8:1-16. doi:10.3389/fonc.2018.00049.
8. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 23:277-86. doi: 10.1016/j.ccr.2013.02.013.
9. Keirsse J, Van Damme H, Van Ginderachter JA, Laoui D. Exploiting tumor-Associated dendritic cell heterogeneity for novel cancer therapies. J Leukoc Biol. (2017) 102:317-24. doi:10.1189/jlb.4MR1116-466R.
10. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van Bossche J Den, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. (2010) 70:5728-39. doi:10.1158/0008-5472.CAN-09-4672.
11. Elpek KG, Cremasco V, Shen H, Harvey CJ, Wucherpfennig KW, Goldstein DR. The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. Cancer Immunol Res. (2014) 2:655-67. doi:10.1158/2326-6066.CIR-13-0209.
12. Kiss M, Van Gassen S, Movahedi K, Saeys Y, Laoui D. Myeloid cell heterogeneity in cancer: not a single cell alike. Cell Immunol. (2018) 330:188-201. doi:10.1016/j.cellimm.2018.02.008.
13. Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell (2018) 33:581-98. doi:10.1016/j.ccell.2018.03.005.
14. D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: The long and winding road to solid tumors review-Article. Cell Death Dis. (2018) 9:282. doi:10.1038/s41419-018-0278-6.
15. Kirkin AF, Dzhandzhugazyan KN, Guldberg P, Fang JJ, Andersen RS, Dahl C, et al. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nat Commun. (2018) 9:1-12doi:10.1038/s41467-018-03217-9.
16. Sharma P, Allison JP. The future of immune checkpoint therapy. Science (2015) 348:56-61. doi: 10.1126/science.aaa8172.
17. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. (2017) 18:e731-e41. doi: 10.1016/S1470-2045(17)30607-1.
18. Wynn TA, Chawla A, Pollard JW. Origins and hallmarks of macrophages: development, homeostasis, and disease. Nature (2013) 496:445-55. doi:10.1038/nature12034.
19. Guilliams M, Scott CL. Does niche competition determine the origin of tissue-resident macrophages? Nat Rev Immunol. (2017) 17:451-60. doi:10.1038/nri.2017.42.
20. Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity (2016) 44:439-49. doi:10.1016/j.immuni.2016.02.024.
21. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 27:462-72. doi:10.1016/j.ccell.2015.02.015.
22. Bolli E, Movahedi K, Laoui D, Van Ginderachter JA. Novel insights in the regulation and function of macrophages in the tumor microenvironment. Curr Opin Oncol. (2017) 29:55-61. doi:10.1097/CCO.0000000000000344.
23. Bowman RL, Klemm F, Akkari L, Pyonteck SM, Quail DF, Dhara S, et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. (2017) 17:2445-59. doi:10.1016/j.celrep.2016.10.052.
24. Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity (2017) 47:323-38. doi:10.1016/j.immuni.2017.07.014.
25. Laoui D, Van Overmeire E, Conza GD, Aldeni C, Keirsse J, Morias Y, et al. Tumor hypoxia does not drive differentiation of tumor-Associated macrophages but rather fine-Tunes the M2-like macrophage population. Cancer Res. (2014) 74:24-30. doi:10.1158/0008-5472.CAN-13-1196.
26. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood (2009) 114:901-14. doi:10.1182/blood-2009-01-200931.
27. Zheng X, Turkowski K, Mora J, Brüne B, Seeger W, Weigert A, et al. Redirecting tumor-Associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget (2015) 8:48436-52. doi:10.18632/oncotarget.17061.
28. Petty AJ, Yang Y. Tumor-Associated macrophages: implications in cancer immunotherapy. Immunotherapy (2017) 9:289-302. doi:10.2217/imt-2016-0135.
29. Narhendorf M, Swirski FK. Abandoning M1/M2 for a network model of macrophage function. Circ Res. (2016) 119:414-7. doi:10.1161/CIRCRESAHA.116.309194.
30. Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell immune map of breast carcinoma reveals diverse phenotypic states driven by the tumor microenvironment. Cell (2017) 174:221994. doi:10.1016/j.cell.2018.05.060.
31. Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, et al. An immune atlas of clear cell renal cell carcinoma. Cell (2017) 169:736-49. doi:10.1016/j.cell.2017.04.016.
32. Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nature (2018) 24:1277-89. doi:10.1038/s41591-018-0096-5.
33. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 23:249-62. doi:10.1016/j.ccr.2013.01.008.
34. Borgoni S, Iannello A, Cutrupi S, Allavena P, D'Incalci M, Novelli F, et al. Depletion of tumor-Associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-Tumor phenotype. Oncoimmunology (2018) 7:e1393596doi:10.1080/2162402X.2017.1393596.
35. Krug S, Abbassi R, Griesmann H, Sipos B, Wiese D, Rexin P, et al. Therapeutic targeting of tumor-Associated macrophages in pancreatic neuroendocrine tumors. Int J Cancer (2018) 143:1806-16. doi:10.1002/ijc.31562.
36. Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. (2018) 46:1141-2. doi:10.1002/cam4.1518.
37. Niu M, Valdes S, Naguib YW, Hursting SD, Cui Z. Tumor-Associated macrophage-mediated targeted therapy of triple-negative breast cancer. Mol Pharm. (2016) 13:1833-42. doi:10.1021/acs.molpharmaceut.5b00987.
38. Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-Associated macrophages. Cancer Res. (2012) 72:4165-77. doi:10.1158/0008-5472.CAN-11-2994.
39. Blykers A, Schoonooghe S, Xavier C, D'hoe K, Laoui D, D'Huyvetter M, et al. PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med. (2015) 56:1265-71. doi:10.2967/jnumed.115.156828.
40. Nuhn L, Bolli E, Massa S, Vandenberghe I, Movahedi K, Devreese B, et al. Targeting protumoral tumor-Associated macrophages with nanobody-functionalized nanogels through strain promoted azide alkyne cycloaddition ligation. Bioconjug Chem. (2018) 29:2394-405. doi:10.1021/acs.bioconjchem.8b00319.
41. Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, et al. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol. (2014) 8:1-9. doi:10.1016/j.molonc.2014.03.016.
42. Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis (2012) 29:585-601. doi:10.1007/s10585-012-9473-5.
43. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-Associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 25:846-59. doi:10.1016/j.ccr.2014.05.016.
44. Laoui D, van Overmeire E, de Baetselier P, van Ginderachter JA, Raes G. Functional relationship between tumor-Associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol. (2014) 5:1-15. doi:10.3389/fimmu.2014.00489.
45. Cannarile MA, Weisser M, Jacob W, Jegg A-M, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer (2017) 5:53. doi:10.1186/s40425-017-0257-y.
46. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. (2013) 19:1264-72. doi:10.1038/nm.3337.
47. Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, et al. M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophagepolarization in the tumor microenvironment. Cancer Res. (2016) 76:35-42. doi:10.1158/0008-5472.CAN-15-0869.
48. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression and improves chemotherapeutic responses. Cancer Res. (2013) 73:1128-41. doi:10.1158/0008-5472.CAN-12-2731.
49. Mantovani A, Marchesi F, Malesci A, Laghi L. Tumor-Associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. (2018) 14:399-416. doi:10.1038/nrclinonc.2016.217.
50. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3K? is a molecular switch that controls immune suppression. Nature (2016) 539:437-42. doi:10.1038/nature19834.
51. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K-? in myeloid cells. Nature (2016) 539:443-7. doi:10.1038/nature20554.
52. Poh AR, Love CG, Masson F, Preaudet A, Tsui C, Whitehead L, et al. Inhibition of hematopoietic cell kinase activity suppresses myeloid cell-mediated colon cancer progression. Cancer Cell (2017) 31:563-75. doi:10.1016/j.ccell.2017.03.006.
53. Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-Tumour macrophages. Nature (2017) 543:428-32. doi:10.1038/nature21409.
54. Singh M, Khong H, Dai Z, Huang X-F, Wargo JA, Cooper ZA, et al. Effective innate and adaptive anti-melanoma immunity through localized TLR-7/8 activation. J Immunol. (2014) 193:4722-31. doi:10.4049/jimmunol.1401160.
55. Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, et al. Synergy of topical Toll-Like Receptor 7 agonist with radiation and low dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res. (2012) 18:6668-78. doi:10.1158/1078-0432.CCR-12-0984.
56. Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR7/8-Agonist-loaded nanoparticles promote the polarization of tumour-Associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. (2018) 1:1-11. doi:10.1038/s41551-018-0236-8.
57. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA. (2012) 109:2066-71. doi:10.1073/pnas.1113099109.
58. Yuan R, Li S, Geng H, Wang X, Guan Q, Li X, et al. Reversing the polarization of tumor-Associated macrophages inhibits tumor metastasis. Int Immunopharmacol. (2017) 49:30-7. doi:10.1016/j.intimp.2017.05.014.
59. Miyamoto N, Mochizuki S, Fujii S, Yoshida K, Sakurai K. Adjuvant activity enhanced by cross-linked CpG-Oligonucleotides in ß-Glucan nanogel and its antitumor effect. Bioconjug Chem. (2017) 28:565-73. doi:10.1021/acs.bioconjchem.6b00675.
60. Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight (2017) 2:e93397. doi:10.1172/jci.insight.93397.
61. Müller E, Christopoulos PF, Halder S, Lunde A, Beraki K, Speth M, et al. Toll-like receptor ligands and interferon-? synergize for induction of antitumor M1 macrophages. Front Immunol. (2017) 8:1383. doi:10.3389/fimmu.2017.01383.
62. Felgner S, Kocijancic D, Frahm M, Weiss S. Bacteria in cancer therapy: Renaissance of an old concept. Int J Microbiol. (2016) 2016:1-14. doi:10.1155/2016/8451728.
63. Kaimala S, Al-sbiei A, Cabral-marques O, Fernandez- MJ. Attenuated bacteria as immunotherapeutic tools for cancer treatment. Front Immunol. (2018) 8:136. doi:10.3389/fonc.2018.00136.
64. Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang C-Y, et al. Re-polarization of tumor-Associated macrophages to pro-inflammatory M 1 macrophages. J Mol Cell Biol. (2012) 4:341-3. doi:10.1093/jmcb/mjs044.
65. Wang P, Xu LJ, Qin JJ, Zhang L, Zhuang GH. MicroRNA-155 inversely correlates with esophageal cancer progression through regulating tumor-Associated macrophage FGF2 expression. Biochem Biophys Res Commun. 503:452-8. doi:10.1016/j.bbrc.2018.04.094.
66. Chaudhuri AA, Yick-Lun So A, Sinha N, Gibson WSJ, Taganov KD, O'Connell RM et al. Mir-125b potentiates macrophage activation. J Immunol. (2011) 187:5062-8. doi:10.4049/jimmunol.1102001.
67. Parayath NN, Parikh A, Amiji MM. Repolarization of tumor-Associated macrophages in a genetically engineered non-small cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating MicroRNA-125b. Nano Lett. 18:3571-9. doi:10.1021/acs.nanolett.8b00689.
68. Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, et al. MiR-511-3p modulates genetic programs of tumor-Associated macrophages. Cell Rep. (2012) 1:141-54. doi:10.1016/j.celrep.2011.12.005.
69. Baer C, Squadrito ML, Laoui D, Thompson D, Hansen SK, Kiialainen A, et al. Suppression of microRNA activity amplifies IFN-?-induced macrophage activation and promotes anti-Tumour immunity. Nat Cell Biol. (2016) 18:790-802. doi:10.1038/ncb3371.
70. De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer (2017) 17:457-74. doi:10.1038/nrc.2017.51.
71. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. (2011) 10:417-27. doi:10.1038/nrd3455.
72. Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS ONE (2014) 9:e99988. doi:10.1371/journal.pone.0099988.
73. Smolarczyk R, Cichon T, Pilny E, Jarosz-Biej M, Poczkaj A, Kulach N, et al. Combination of anti-vascular agent-DMXAA and HIF-1a inhibitor-digoxin inhibits the growth of melanoma tumors. Sci Rep. (2018) 8:1-9. doi:10.1038/s41598-018-25688-y.
74. Lei X, Chen M, Li X, Huang M, Nie Q, Ma N, et al. A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype. Cancer Lett. (2018) 418:239-49. doi:10.1016/j.canlet.2018.01.016.
75. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-Tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA. (2016) 113:4476-81. doi:10.1073/pnas.1525360113.
76. Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival inglioblastoma by altering macrophages. Proc Natl Acad Sci USA. (2016) 113:4470-75. doi:10.1073/pnas.1525349113.
77. Zhu X, Yang J, Gao Y, Wu C, Yi L, Li G, et al. The dual effects of a novel peptibody on angiogenesis inhibition and M2 macrophage polarization on sarcoma. Cancer Lett. (2018) 416:1-10. doi:10.1016/j.canlet.2017.10.043.
78. Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Rmili CW, Kiialainen A, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. (2017) 9:eaak9670. doi:10.1126/scitranslmed.aak9670.
79. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 19:31-44. doi:10.1016/j.ccr.2010.11.009.
80. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum R, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 331:1612-6. doi:10.1126/science.1198443.
81. Hoves S, Ooi C-H, Wolter C, Sade H, Bissinger S, Schmittnaegel M, et al. Rapid activation of tumor-Associated macrophages boosts preexisting tumor immunity. J Exp Med. (2018) 215:859-76. doi:10.1084/jem.20171440.
82. Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, et al. Myeloid-Targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med. (2018) 215:877-93. doi:10.1084/jem.20171435.
83. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, et al. Reprogramming tumor-Associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. (2016) 15:2000-11. doi:10.1016/j.celrep.2016.04.084.
84. Carmona-Fontaine C, Deforet M, Akkari L, Thompson CB, Joyce JA, Xavier JB. Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci USA. (2017) 114:2934-9. doi:10.1073/pnas.1700600114.
85. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell (2013) 24:695-709. doi:10.1016/j.ccr.2013.11.007.
86. Edris B, Weiskopf K, Volkmer AK, Volkmer J-P, Willingham SB, Contreras-Trujillo H, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA. (2012) 109:6656-61. doi:10.1073/pnas.1121629109.
87. Sikic BI, Narayanan S, Colevas D, Padda SK, Fisher GA, Supan D, et al. A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. (2017) 34:3019. doi:10.1200/JCO.2016.34.15-suppl.3019.
88. Weiskopf K, Ring AM, Ho CCM, Volkmer J, Levin A, van de Rijn M., Volkmer A. K., et al. Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science (2013) 341:88-91. doi:10.1126/science.1238856.
89. Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, et al. Chloroquine modulates antitumor immune response by resetting tumor-Associated macrophages toward M1 phenotype. Nat Commun. (2018) 8:1-15. doi:10.1038/s41467-018-03225-9.
90. Chakraborty P, Chatterjee S, Ganguly A, Saha P, Adhikary A, Das T, et al. Reprogramming of TAM toward proimmunogenic type through regulation of MAP kinases using a redox-Active copper chelate. J Leukoc Biol. (2012) 91:1-11. doi:10.1189/jlb.0611287.
91. Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, Chakarov S, et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity (2016) 45:669-84. doi:10.1016/j.immuni.2016.08.015.
92. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. (2013) 31:1-16. doi: 10.1146/annurev-immunol-020711-074950.
93. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. (2014) 14:392-404. doi:10.1038/nri3671.
94. Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun. (2016) 7:1-17. doi:10.1038/ncomms13720.
95. Villani A, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes and progenitors. Science (2017) 356:1-31. doi:10.1126/science.aah4573.
96. Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity (2013) 38:336-48. doi:10.1016/j.immuni.2012.10.01.
97. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. (2015) 15:471-85. doi:10.1038/nri3865.
98. Bakdash G, Buschow SI, Gorris MAJ, Halilovic A, Hato SV, Sko ld AE, et al. Expansion of a BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. Cancer Res. (2016) 76:4332-46. doi:10.1158/0008-5472.CAN-15-1695.
99. Bennaceur K, Chapman J, Brikci-Nigassa L, Sanhadji K, Touraine J louis, Portoukalian J. Dendritic cells dysfunction in tumour environment. Cancer Lett. (2008) 272:186-96. doi:10.1016/j.canlet.2008.05.017.
100. Conejo-Garcia JR, Rutkowski MR, Cubillos-Ruiz JR. State-of-The-Art of regulatory dendritic cells in cancer. Pharmacol Ther. (2016) 164:97-104. doi:10.1016/j.pharmthera.2016.04.003.
101. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 26:638-52. doi:10.1016/j.ccell.2014.09.007.
102. Lavin Y, Kobayashi S, Leader A, Amir E-AD, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell (2017) 169:750-65. doi:10.1016/j.cell.2017.04.014.
103. Garg AD, Coulie PG, Van Den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. (2017) 38:577-93. doi:10.1016/j.it.2017.05.006.
104. Garg AD, Perez MV, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, et al. Trial watch: dendritic cell-based anticancer therapy. Oncoimmunology (2017) 6:e1328341. doi:10.4161/21624011.2014.963424.
105. Ahmed S, Bae Y-S. Dendritic cell-based therapeutic cancer vaccines: Past, present and future. Clin Exp Vaccine Res. (2014) 3:113-6. doi:10.7774/cevr.2014.3.2.113.
106. Bol KF, Schreibelt G, Gerritsen WR, De Vries IJM, Figdor CG. Dendritic cell-based immunotherapy: State of the art and beyond. Clin Cancer Res. (2016) 22:1897-906. doi:10.1158/1078-0432.CCR-15-1399.
107. Cheever MA, Higano CS. PROVENGE (sipuleucel-T) in prostate cancer: The first FDA-Approved therapeutic cancer vaccine. Clin Cancer Res. (2011) 17:3520-6. doi: 10.1158/1078-0432.CCR-10-3126.
108. Abraham RS, Mitchell DA. Gene-modified dendritic cell vaccines for cancer. Cytotherapy (2016) 18:1446-55. doi:10.1016/j.jcyt.2016.09.009.
109. Jeught K Van der, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 6:1359-81. doi:10.18632/oncotarget.3204.
110. Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glio. Immunotherapy (2016) 8:1-16. doi:10.1126/scitranslmed.aae0105.
111. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. (2012) 31:1062-79. doi:10.1038/emboj.2011.497.
112. Hradilova N, Sadilkova L, Palata O, Mysikova D, Mrazkova H, Lischke R, et al. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS ONE (2017) 12: E0171539. doi:10.1371/journal.pone.0171539.
113. Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res. (2016) 4:146-56. doi10.1158/2326-6066.CIR-15-0163.
114. Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Marmol V, et al. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. J Transl Med. (2016) 14:1-14. doi:10.1186/s12967-016-0990-x.
115. Wilgenhof S, Corthals J, Heirman C, Van Baren N, Lucas S, Kvistborg P, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patientswith pretreated advanced melanoma. J Clin Oncol. (2016) 34:1330-8. doi:10.1200/JCO.2015.63.4121.
116. Ma DY, Clark EA. The role of CD40 and CD40L in dendritic cells. Semin Immunol. (2009) 21:265-72.
117. Lapteva N, Seethammagari MR, Hanks BA, Jiang H, Levitt JM, Slawin KM, et al. Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 ligation. Cancer Res. (2007) 67:10528-37. doi:10.1158/0008-5472.CAN-07-0833.
118. Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Langer R, et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with toll-like receptor agonists as a treatment for melanoma. PLoS ONE (2009) 4:e7334. doi:10.1371/journal.pone.0007334.
119. Onai N, Obata-Onai A, Schmid MA, Ohteki T, Jarrossay D, Manz MG. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol. (2007) 8:1207-16. doi:10.1038/ni1518.
120. Riediger C, Wingender G, Knolle P, Aulmann S, Stremmel W, Encke J. Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model. J Cancer Res Clin Oncol. (2013) 139:2097-110. doi:10.1007/s00432-013-1532-z.
121. Tel J, Aarntzen EHJG, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-Cell responses in melanoma patients. Cancer Res. (2013) 73:1063-75. doi:10.1158/0008-5472.CAN-12-2583.
122. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EHJG, Duiveman-De Boer T, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res. (2016) 22:2155-66. doi:10.1158/1078-0432.CCR-15-2205.
123. Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin Cancer Res. (2011) 17:3984-92. doi:10.1158/1078-0432.CCR-10-3262.
124. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity (2016) 44:924-38. doi:10.1016/j.immuni.2016.03.012.
125. Luo Z, Wang C, Yi H, Li P, Pan H, Liu L, Cai L, Ma Y. Nanovaccine loaded with poly I: C and STAT3 siRNA robustly elicits anti-Tumor immune responses through modulating tumor-Associated dendritic cells in vivo. Biomaterials (2015) 38:50-60. doi:10.1016/j.biomaterials.2014.10.050.
126. Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, et al. CD40-Targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-Tumor responses. Biomaterials (2015) 40:88-97. doi:10.1016/j.biomaterials.2014.10.053.
127. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol. (2001) 14:604-8. doi:10.1038/modpathol.3880358.
128. Sluijter BJR, van den Hout MFCM, Koster BD, van Leeuwen PAM, Schneiders FL, van de Ven R, et al. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: Recruitment and activation of BDCA3/CD141+ dendritic cells and enhanced cross-presentation. Cancer Immunol Res. (2015) 3:495-505. doi:10.1158/2326-6066.CIR-14-0165.
129. Mould RC, AuYeung AWK, Van Vloten JP, Susta L, Mutsaers AJ, Petrik JJ, et al. Enhancing immune responses to cancer vaccines using multi-site injections. Sci Rep. (2017) 7:3-10. doi:10.1038/s41598-017-08665-9.
130. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective cancer immunotherapy. Anal Chem. (2015) 25:368-79. doi:10.1016/j.cell.2016.12.022.
131. Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature (2016) 534:396-401. doi:10.1038/nature18300.
132. Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell (2018) 172:1022-8.e14. doi:10.1016/j.cell.2018.01.004.
133. Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. (2017) 28:xii44-xii55. doi:10.1093/annonc/mdx237.
134. Shen M, Ren X. New insights into the biological impacts of immune cell-derived exosomes within the tumor environment. Cancer Lett. (2018) 431:115-22. doi:10.1016/j.canlet.2018.05.040.
135. Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. (2017) 67:739-48. doi:10.1016/j.jhep.2017.05.019.
136. Chen Gang EL. Chemoimmunotherapy:reengineering tumor immunity. Cancer Immunol Immunother. (2013) 33:203-16. doi:10.1007/s00262-012-1388-0.
137. Ishii H, Chikamatsu K, Igarashi S, Takahashi H, Sakamoto K, Higuchi H, et al. Establishment of synergistic chemoimmunotherapy for head and neck cancer using peritumoral immature dendritic cell injections and low-dose chemotherapies. Transl Oncol. (2018) 11:18-23. doi:10.1016/j.tranon.2017.11.006.
138. Cornelissen R, Hegmans JPJJ, Maat APWM, Kaijen-Lambers MEH, Bezemer K, Hendriks RW, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. (2016) 193:1023-31. doi:10.1164/rccm.201508-1573OC.
139. Coffelt SB, Wellenstein MD, De Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer (2016) 16:431-46. doi:10.1038/nrc.2016.52.
140. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest. (2012) 122:3127-44. doi:10.1172/JCI61067.
141. Mouchemore KA, Anderson RL, Hamilton JA. Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J. (2018) 285:665-79. doi:10.1111/febs.14206.
142. Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R. Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. Proc Natl Acad Sci USA. (2016) 113:11300-5. doi:10.1073/pnas.1613187113.
143. Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: Prognostic role and therapeutic strategies. Mol Cancer (2017) 16:1-7. doi:10.1186/s12943-017-0707-7.
144. Moses K, Brandau S. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol. (2016) 28:187-96. doi:10.1016/j.smim.2016.03.018.
145. Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol. (2015) 98:913-22. doi:10.1189/jlb.4RI0515-204R.
146. Ibrahim SA, Katara GK, Kulshrestha A, Jaiswal MK, Amin MA, Beaman KD. Breast cancer associated A2 isoform vacuolar ATPase immunomodulates neutrophils: Potential role in tumor progression. Oncotarget (2015) 6:33033-45. doi:10.18632/oncotarget.5439.
147. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, et al. Tumor-Associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. (2014) 124:5466-80. doi: 10.1172/JCI77053.
148. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, et al. Prognostic role of neutrophil-To-lymphocyte ratio in solid tumors: A systematic review and meta-Analysis. J Natl Cancer Inst. (2014) 106:dju124. doi:10.1093/jnci/dju124.
149. Yutong H, Xiaoli X, Shumei L, Shan S, Di L, Baoen S. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with esophageal cancer in a high incidence area in China. Arch Med Res. (2015) 46:557-63. doi:10.1016/j.arcmed.2015.09.003.
150. Najjar M, Agrawal S, Emond JC, Halazun KJ. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J Hepatocell Carcinoma (2018) 5:17-28. doi: 10.2147/JHC.S86792.
151. Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor immunology. Trends Immunol. (2012) 33:496-504. doi:10.1016/j.it.2012.05.007.
152. Engblom C, Pfirschke C, Zilionis R, Da Silva Martins J, Bos SA, Courties G, et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhighneutrophils. Science (2017) 358:eaal5081. doi:10.1126/science.aal5081.
153. Mishalian I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17-A new mechanism of impaired antitumor immunity. Int J Cancer (2014) 135:1178-86. doi: 10.1002/ijc.28770.
154. Yan J, Kloecker G, Fleming C, Bousamra M, Hansen R, Hu X, et al. Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells. Oncoimmunology (2014) 3:e950163. doi:10.4161/15384101.2014.950163.
155. Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature (2015) 528:413-7. doi:10.1038/nature16140.
156. Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. (2011) 179:1455-70. doi:10.1016/j.ajpath.2011.05.031.
157. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-b regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. (2010) 120:1151-64. doi:10.1172/JCI37223.
158. Benevides L, Da Fonseca DM, Donate PB, Tiezzi DG, De Carvalho DD, De Andrade JM, et al. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res (2015) 75:3788-99. doi:10.1158/0008-5472.CAN-15-0054.
159. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Worthen GS, et al. Polarization of tumor-Associated neutrophil (TAN) phenotype by TGF-ß: "N1" versus "N2" TAN. Cancer Cell (2009) 16:183-94. doi:10.1016/j.ccr.2009.06.017.
160. Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, Von Köckritz-Blickwede M, et al. Type i IFNs induce anti-Tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer (2016) 138:1982-93doi:10.1002/ijc.29945.
161. Pylaeva E, Lang S, Jablonska J. The essential role of type I interferons in differentiation and activation of tumor-Associated neutrophils. Front Immunol. (2016) 7:629. doi:10.3389/fimmu.2016.00629.
162. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. (1986) 315:1650-9.
163. Souto JC, Vila L, Bru A. Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev. (2009) 31:311-63. doi:10.1002/med.20185.
164. Im JH, Tapmeier T, Balathasan L, Gal A, Yameen S, Hill S, et al. G-CSF rescues tumor growth and neo-Angiogenesis during liver metastasis under host angiopoietin-2 deficiency. Int J Cancer (2013) 132:315-26. doi:10.1002/ijc.27677.
165. Pickup MW, Owens P, Gorska AE, Chytil A, Ye F, Shi C, et al. Development of aggressive pancreatic ductal adenocarcinomas depends on granulocyte-colony stimulating factor secretion in carcinoma cells. Cancer Immunol Res. (2017) 5:718-29. doi: 10.1158/2326-6066.CIR-16-0311.
166. Li W, Zhang X, Chen Y, Xie Y, Liu J, Feng Q, et al. G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-Associated colorectal cancers. Protein Cell (2016) 7:130-40. doi:10.1007/s13238-015-0237-2.
167. Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, et al. Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumor Biol. (2017) 39:1010428317699797. doi:10.1177/1010428317699797.
168. Granot Z, Henke E, Comen E, King T, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 20:300-14. doi:10.1016/j.ccr.2011.08.012.
169. Bajrami B, Zhu H, Kwak H-J, Mondal S, Hou Q, Geng G, et al. G-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling. J Exp Med. (2016) 213:1999-2018. doi:10.1084/jem.20160393.
170. Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, et al. NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol. (2015) 9:1140-54. doi:10.1016/j.molonc.2015.02.004.
171. López-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti R. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene (2013) 32:1752-60. doi:10.1038/onc.2012.201.
172. Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. (2017) 7:750-65. doi10.1158/2159-8290.CD-16-0778.
173. Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration resistant prostate cancer. Nature (2017) 344:1173-8. doi:10.1038/nature21676.
174. Devapatla B, Sharma A, Woo S. CXCR2 inhibition combined with sorafenib improved antitumor and antiangiogenic response in preclinical models of ovarian cancer. PLoS ONE (2015) 10:e0139237. doi:10.1371/journal.pone.0139237.
175. Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity (2017) 47:789-802.e9. doi:10.1016/j.immuni.2017.09.012.
176. Finisguerra V, Conza G Di, Matteo M Di, Serneels J, Thompson AAR, Wauters E, et al. MET is required for the recruitment of anti-Tumoural neutrophils. Nature (2015) 522:349-53. doi:10.1038/nature14407.
177. Powell DR, Huttenlocher A. Neutrophils in the tumor microenvironment. Trends Immunol. (2016) 37:41-52. doi:10.1016/j.it.2015.11.008.
178. Singhal S, Bhojnagarwala PS, O'Brien S, Moon EK, Garfall AL, Rao A, et al. Origin and role of a subset of tumor-Associated neutrophils with antigen presenting cell features (hybrid TANs) in early- stage human lung cancer. Cancer Cell (2016) 30:120-35. doi:10.1016/j.ccell.2016.06.001.
179. Robertson AL, Holmes GR, Bojarczuk AN, Burgon J, Loynes CA, Chimen M, et al. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci Transl Med. (2014) 6:225-9. doi:10.1126/scitranslmed.3007672.
180. Tauzin S, Starnes TW, Becker FB, Lam P Ying, Huttenlocher A. Redox and Src family kinase signaling control leukocyte wound attraction and neutrophil reverse migration. J Cell Biol. (2014) 207:589-98. doi:10.1083/jcb.201408090.
181. Colom B, Bodkin JV, Beyrau M, Woodfin A, Ody C, Rourke C, et al. Neutrophil elastase axis drives neutrophil reverse transendothelial cell migration in vivo. Immunity (2015) 42:1075-86. doi:10.1016/j.immuni.2015.05.010.
182. Lerman I, Hammes SR. Neutrophil elastase in the tumor microenvironment. Steroids (2018) 133:96-101. doi:10.1016/j.steroids.2017.11.006.
183. Punt S, Fleuren GJ, Kritikou E, Lubberts E, Trimbos JB, Jordanova ES, et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology (2015) 4:984539. doi: 10.4161/2162402X.2014.984539.
184. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. (2016) 7:12150. doi:10.1038/ncomms12150.
185. Movahedi K, Guilliams M, Van Den Bossche J, Van Den Bergh R, Beschin A, De Baetselier P, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 111:4233-44. doi:10.1182/blood-2007-07-099226.
186. Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, et al. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol. (2013) 43:2930-42. doi:10.1002/eji.201343349.
187. Dorhoi A, Du Plessis N. Monocytic myeloid-derived suppressor cells in chronic infections. Front Immunol. (2018) 8:1895. doi:10.3389/fimmu.2017.01895.
188. Iacobaeus E, Douagi I, Jitschin R, Marcusson-Ståhl M, Törnqvist Andrén A, Gavin C, et al. Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis. Immunol Cell Biol. (2018) 96:820-30. doi:10.1111/imcb.12042.
189. Salminen A, Kaarniranta K, Kauppinen A. The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer's disease. Cell Mol Life Sci. (2018) 75:3099-120. doi:10.1007/s00018-018-2844-6.
190. Van Ginderachter JA, Beschin A, De Baetselier P, Raes G. Myeloid-derived suppressor cells in parasitic infections. Eur J Immunol. (2010) 40:2976-85. doi:10.1002/eji.201040911.
191. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. (2012) 12:253-68. doi:10.1038/nri3175.
192. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. (2012) 2:628-39. doi: 10.1016/j.celrep.2012.08.006.
193. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPß transcription factor. Immunity (2010) 32:790-802. doi: 10.1016/j.immuni.2010.05.010.
194. Maenhout SK, Van Lint S, Emeagi PU, Thielemans K, Aerts JL. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int J Cancer (2014) 134:1077-90. doi: 10.1002/ijc.28449.
195. Zhang S, Ma X, Zhu C, Liu L, Wang G, Yuan X. The role of myeloid-derived suppressor cells in patients with solid tumors: A meta-Analysis. PLoS ONE (2016) 11:e0164514. doi:10.1371/journal.pone.0164514.
196. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 6:409-21. doi:10.1016/j.ccr.2004.08.031.
197. Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, et al. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. (2010) 70:6139-49. doi:10.1158/0008-5472.CAN-10-0706.
198. Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, et al. Tumour-infiltrating Gr-1 + myeloid cells antagonize senescence in cancer. Nature (2014) 515:134-37. doi:10.1038/nature13638.
199. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Gomez AF, Mesa C, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. (2010) 40:22-35. doi:10.1002/eji.200939903.
200. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. (2011) 208:1949-62. doi:10.1084/jem.20101956.
201. Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, et al. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett. (2016) 371:117-24. doi: 10.1016/j.canlet.2015.10.040.
202. Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, et al. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res. (2014) 2014:659294. doi:10.1155/2014/659294.
203. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. (2014) 63:247-57. doi:10.1007/s00262-013-1508-5.
204. Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. (2017) 85:117-25. doi:10.1016/j.jaut.2017.07.010.
205. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. (2016) 37:208-20. doi: 10.1016/j.it.2016.01.004.
206. Atretkhany K-SN, Drutskaya MS. Myeloid-derived suppressor cells and proinflammatory cytokines as targets for cancer therapy. Biochemistry (2016) 81:1274-83. doi:10.1134/S0006297916110055.
207. Zoso A, Mazza EMC, Bicciato S, Mandruzzato S, Bronte V, Serafini P, et al. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol. (2014) 44:3307-19. doi:10.1002/eji.201444522.
208. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. (2011) 32:345-9. doi: 10.1016/j.it.2011.05.003.
209. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. (2009) 182:240-9. doi:10.4049/jimmunol.182.1.240.
210. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanisms regulating reactive oxygen species in tumor induced myeloid-derived suppressor cells: MDSC and ROS in cancer. J Immunol. (2009) 182:5693-701. doi:10.4049/jimmunol.0900092.
211. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a novel mechanism of CD8+ T cell tolerance in cancer. Nat Med. (2007) 13:828-35. doi:10.1038/nm1609.
212. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through ido expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. (2013) 190:3783-97. doi:10.4049/jimmunol.1390024.
213. Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Bossman SAJFH, Ter Laan M, et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuro Oncol. (2016) 18:1253-64. doi:10.1093/neuonc/now034.
214. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. (2008) 205:2235-49. doi:10.1084/jem.20080132.
215. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. (2008) 181:4666-75. doi:10.4049/jimmunol.181.7.4666.
216. Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, et al. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials (2016) 96:47-62. doi:10.1016/j.biomaterials.2016.04.010.
217. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. (2010) 70:3052-61. doi:10.1158/0008-5472.CAN-09-3690.
218. Huang X, Cui S, Shu Y. Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model. Immunol Res. (2016) 64:160-70. doi:10.1007/s12026-015-8734-1.
219. Qin H, Lerman B, Sakamaki I, Wei G, Cha S, Rao SS, et al. Generation of a novel therapeutic peptide that depletes MDSC in tumor-bearing mice. Nat Med. (2014) 20:676-81. doi:10.1038/nm.3560.
220. Espagnolle N, Barron P, Mandron M, Blanc I, Bonnin J, Agnel M, et al. Specific inhibition of the VEGFR-3 tyrosine kinase by SAR131675 reduces peripheral and tumor associated immunosuppressive myeloid cells. Cancers (2014) 6:472-90. doi:10.3390/cancers6010472.
221. Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, et al. Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment HHS Public Access. Cancer Res. (2016) 15:2125-36. doi:10.1158/0008-5472.CAN-15-1490.
222. Lee BR, Kwon BE, Hong EH, Shim A, Song JH, Kim HM, et al. Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells. Cancer Lett. (2016) 381:156-64. doi: 10.1016/j.canlet.2016.07.012.
223. Foubert P, Kaneda MM, Varner JA. PI3K? activates integrin a 4 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol Res. (2017) 5:957-68. doi:10.1158/2326-6066.CIR-17-0143.
224. Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin Cancer Res. (2017) 23:2942-50. doi:10.1158/1078-0432.CCR-16-1784.
225. Guislain A, Gadiot J, Kaiser A, Jordanova ES, Broeks A, Sanders J, et al. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother. (2015) 64:1241-50. doi: 10.1007/s00262-015-1735-z.
226. Kim SH, Li M, Trousil S, Zhang Y, Pasca di Magliano M, Swanson KD, et al. Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-Tumor activity of PD-1 blockade in melanoma. J Invest Dermatol. (2017) 137:1740-8. doi:10.1016/j.jid.2017.03.033.
227. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, Brian L, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. (2014) 74:5057-69. doi:10.1158/0008-5472.CAN-13-3723.
228. Zhang QQ, Hu XW, Liu YL, Ye ZJ, Gui YH, Zhou DL, et al. CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment. Sci Rep. (2015) 5:1-12. doi:10.1038/srep15948.
229. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA. (2014) 111:11774-9. doi:10.1073/pnas.1410626111.
230. Califano JA, Khan Z, Noonan KA, Rudraraju L, Wang H, Goodman S, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. (2015) 21:30-8. doi:10.1158/1078-0432.CCR-14-1716.
231. Condamine T, Kumar V, Ramachandran IR, Youn J, Celis E, Finnberg N, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R - mediated apoptosis. J Clin Invest. (2014) 124:2626-39. doi:10.1172/JCI74056.
232. Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Marone G, et al. Are masT cells MASTers in cancer? Front Immunol. (2017) 8:424. doi:10.3389/fimmu.2017.00424.
233. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, et al. MasT cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE (2010) 5:e8922. doi:10.1371/journal.pone.0008922.
234. Lee M, Park C-S, Lee Y-R, Im S-A, Song S, Lee C-K. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. (2014) 37:1234-40. doi:10.1007/s12272-014-0379-4.
235. Spinetti T, Spagnuolo L, Mottas I, Secondini C, Treinies M, Rüegg C, et al. TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. Oncoimmunology (2016) 5:e1230578. doi:10.1080/2162402X.2016.1230578.
236. Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, et al. Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals. Clin Cancer Res. (2018) 24:62-72. doi:10.1158/1078-0432.CCR-17-0357.
237. Wang J, Shirota Y, Bayik D, Shirota H, Tross D, Gulley JL, et al. Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells. J Immunol. (2015) 194:4215-21. doi:10.4049/jimmunol.1402004.
238. Zambirinis CP, Levie E, Nguy S, Avanzi A, Barilla R, Xu Y, et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J Exp Med. (2015) 212:2077-94. doi:10.1084/jem.20142162.
239. Shime H, Maruyama A, Yoshida S, Takeda Y, Matsumoto M, Seya T. Toll-like receptor 2 ligand and interferon-? suppress anti-Tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells. Oncoimmunology (2018) 7:1-13. doi:10.1080/2162402X.2017.1373231.
240. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Boireau W, et al. Membrane associated Hsp72 from tumor derived exosomes mediates STAT3 depedent immunosuppressive function of mouse and human myeloid derived suppressor cells. J Clin Invest. (2010) 120:467-71. doi: 10.1172/JCI40483.
241. Janssen N, Speigl L, Pawelec G, Niessner H, Shipp C. Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by melanoma cells. Cell Immunol. (2018) 327:68-76. doi:10.1016/j.cellimm.2018.02.012.
242. Albeituni SH, Ding C, Liu M, Hu X, Luo F, Kloecker G, et al. Yeast-derived particulate ß-glucan treatment subverts the suppression of myeloid-derived suppressor cells by inducing PMN-MDSC apoptosis and M-MDSC differentiation to APC in cancer. J Immunol. (2016) 196:2167-80. doi: 10.1016/j.cogdev.2010.08.003.
243. Yin Y, Huang X, Lynn KD, Thorpe PE. Phosphatidylserine-Targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol Res. (2013) 1:256-68. doi:10.1158/2326-6066.CIR-13-0073.
244. Zhou J, Donatelli SS, Gilvary DL, Tejera MM, Eksioglu EA, Chen X, et al. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. Sci Rep. (2016) 6:29521. doi:10.1038/srep29521.
245. Yaddanapudi K, Rendon BE, Lamont G, Kim EJ, Al Rayyan N, Richie J, et al. MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation. Cancer Immunol Res. (2016) 4:101-12. doi:10.1158/2326-6066.CIR-15-0070-T.
246. Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res. (2015) 3:136-48. doi:10.1158/2326-6066.CIR-14-0036.
247. Du Four S, Maenhout SK, De Pierre K, Renmans D, Niclou SP, Thielemans K, et al. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology (2015) 4:e998107. doi:10.1080/2162402X.2014.998107.
248. Gentles AJ, Newman AM, Liu CL, Bratman SV, Diehn M, West RB, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. (2015) 21:938-45. doi: 10.1038/nm.3909.
249. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. (2017) 18:248-62. doi:10.1016/j.celrep.2016.12.019.